Spero Therapeutics announces $51.7 million in new financing
Cambridge-based Spero Therapeutics, a biopharmaceutical company that develops treatments for antibiotic-resistant bacterial infections, has raised $51.7 million in new capital.
The funding round was led by corporate venture capital firm GV, formerly known as Google Ventures. RA Capital Management and Rock Springs Capital also participated in the Series C financing.
CEO Ankit Mahadevia, MD, said the money will be used for clinical trials.
“One [asset] in particular that we’d highlight is the Potentiator platform, which takes existing antibiotics and adds [the] ability to treat multi-drug resistance to those antibiotics,” Mahadevia said.
The announcement follows a report from the World Health Organization listing the 12 families of antibiotic-resistant bacteria that pose the greatest threat to human health.
“Each pathogen on that list is addressed by a member of our pipeline,” Mahadevia said.